Histological study of the biodynamics of iron oxide nanoparticles with different diameters

Tsuchiya, Keiko; Nitta, Norihisa; Sonoda, Akinaga; Nitta-Seko, Ayumi; Ohta, Shin‐ichi; Otani, Hideji; Takahashi, Masashi; Murata, Kiyoshi; Murase, Katsutoshi; Nohara, Satoshi; Mukaisho, Ken‐ichi

doi:10.2147/ijn.s22189

Cited by 26 publications

(25 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other injection routes such as intra-peritoneal (IP) 255-257 , retroorbital, 51, 58 , intravitreal (inner cavity of the eyes for intraocular drug delivery), 258, 259 intra-muscular and subcutaneous injections have also been used as alternative methods for administration of the IONPs. Tsuchiya et al .…”

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

et al. 2015

View full text Add to dashboard Cite

Iron oxide nanoparticles (IONPs) have been extensively used during the last two decades, either as effective bio-imaging contrast agents or as carriers of biomolecules such as drugs, nucleic acids and peptides for controlled delivery to specific organs and tissues. Most of these novel applications require elaborate tuning of the physiochemical and surface properties of the IONPs. As new IONPs designs are envisioned, synergistic consideration of the body's innate biological barriers against the administered nanoparticles and the short and long-term side effects of the IONPs become even more essential. There are several important criteria (e.g. size and size-distribution, charge, coating molecules, and plasma protein adsorption) that can be effectively tuned to control the in vivo pharmacokinetics and biodistribution of the IONPs. This paper reviews these crucial parameters, in light of biological barriers in the body, and the latest IONPs design strategies used to overcome them. A careful review of the long-term biodistribution and side effects of the IONPs in relation to nanoparticle design is also given. While the discussions presented in this review are specific to IONPs, some of the information can be readily applied to other nanoparticle systems, such as gold, silver, silica, calcium phosphates and various polymers.

show abstract

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

“…Tsuchiya et al . 255 showed that intra-peritoneally injected IONPs mainly distributed in liver, lymph nodes and lung. Kim et al 256 showed that IP injected IONPs can pass the blood-brain- and blood–testis-barriers in addition to usual accumulation in MPS organs.…”

Section: Ionps Pharmacokineticsmentioning

confidence: 99%

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Khurana et al as the liver (31,32), the spleen (31), lymph nodes (32,33), and bone marrow (34)(35)(36). The relatively large nanoparticles, which have a size on the order of plasma proteins, initially distribute in the blood pool, where they cause strong T1 and T2 relaxation time enhancement (37).…”

Section: Molecular Imaging: Mr Imaging Monitoring Of Macrophage Migramentioning

confidence: 99%

Intravenous Ferumoxytol Allows Noninvasive MR Imaging Monitoring of Macrophage Migration into Stem Cell Transplants

Khurana¹,

Nejadnik²,

Gawande³

et al. 2012

Radiology

View full text Add to dashboard Cite

Purpose:To develop a clinically applicable imaging technique for monitoring differential migration of macrophages into viable and apoptotic matrix-associated stem cell implants (MASIs) in arthritic knee joints. Materials andMethods:With institutional animal care and use committee approval, six athymic rats were injected with intravenous ferumoxytol (0.5 mmol iron per kilogram of body weight) to preload macrophages of the reticuloendothelial system with iron oxide nanoparticles. Forty-eight hours later, all animals received MASIs of viable adipose-derived stem cells (ADSCs) in an osteochondral defect of the right femur and mitomycin-pretreated apoptotic ADSCs in an osteochondral defect of the left femur. One additional control animal each received intravenous ferumoxytol and bilateral scaffold-only implants (without cells) or bilateral MASIs without prior ferumoxytol injection. All knees were imaged with a 7.0-T magnetic resonance (MR) imaging unit with T2-weighted fast spin-echo sequences immediately after, as well as 2 and 4 weeks after, matrix-associated stem cell implantation. Signal-to-noise ratios (SNRs) of viable and apoptotic MASIs were compared by using a linear mixedeffects model. MR imaging data were correlated with histopathologic findings. Results:All ADSC implants showed a slowly decreasing T2 signal over 4 weeks after matrix-associated stem cell implantation. SNRs decreased significantly over time for the apoptotic implants (SNRs on the day of matrix-associated stem cell implantation, 2 weeks after the procedure, and 4 weeks after the procedure were 16.9, 10.9, and 6.7, respectively; P = .0004) but not for the viable implants (SNRs on the day of matrix-associated stem cell implantation, 2 weeks after the procedure, and 4 weeks after the procedure were 17.7, 16.2, and 15.7, respectively; P = .2218). At 4 weeks after matrix-associated stem cell implantation, SNRs of apoptotic ADSCs were significantly lower than those of viable ADSCs (mean, 6.7 vs 15.7; P = .0013). This corresponded to differential migration of ironloaded macrophages into MASIs. Conclusion:Iron oxide loading of macrophages in the reticuloendothelial system by means of intravenous ferumoxytol injection can be utilized to monitor differential migration of bone marrow macrophages into viable and apoptotic MASIs in a rat model.

show abstract

“…Of note is the fact that the size of iron oxide nanoparticles determines the efficiency of cell up-take, with much higher labeling efficiency for small nanoparticles ca. 70 nm diameter (SPIO), than for ultra-small iron oxide nanoparticles (USPIO) [137]. One of the SPIO formulations (Feridex®) approved by the Food and Drug Administration (FDA) in 1996 as a liver contrast agent, following the development of methods that facilitated the labeling of non-phagocytes, including stem cells, was extensively used and characterized in preclinical research, with the intention to use Feridex® clinically thereafter [138–140].…”

Section: Stem Cell Labels and Tracersmentioning

confidence: 99%

Personalized nanomedicine advancements for stem cell tracking

Janowski¹,

Bulte²,

Walczak³

2012

Advanced Drug Delivery Reviews

View full text Add to dashboard Cite

Histological study of the biodynamics of iron oxide nanoparticles with different diameters

Cited by 26 publications

References 30 publications

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles

Intravenous Ferumoxytol Allows Noninvasive MR Imaging Monitoring of Macrophage Migration into Stem Cell Transplants

Personalized nanomedicine advancements for stem cell tracking

Contact Info

Product

Resources

About